Market News

Mastercard (MA) Shareholder Autus Asset Management Lowered Its Holding; Vertex Pharmaceuticals (Call) (VRTX) Shareholder Artal Group Sa Has Lowered Position

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo

Autus Asset Management Llc decreased its stake in Mastercard Incorporated (MA) by 5.66% based on its latest 2018Q1 regulatory filing with the SEC. Autus Asset Management Llc sold 4,572 shares as the company’s stock rose 7.48% while stock markets declined. The institutional investor held 76,176 shares of the business services company at the end of 2018Q1, valued at $13.34M, down from 80,748 at the end of the previous reported quarter. Autus Asset Management Llc who had been investing in Mastercard Incorporated for a number of months, seems to be less bullish one the $208.30 billion market cap company. The stock increased 0.11% or $0.22 during the last trading session, reaching $199.53. About 4.16M shares traded or 11.23% up from the average. Mastercard Incorporated (NYSE:MA) has risen 56.80% since June 17, 2017 and is uptrending. It has outperformed by 44.23% the S&P500.

Artal Group Sa decreased its stake in Vertex Pharmaceuticals Inc (Call) (VRTX) by 50% based on its latest 2018Q1 regulatory filing with the SEC. Artal Group Sa sold 100,000 shares as the company’s stock declined 7.10% with the market. The institutional investor held 100,000 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $16.30M, down from 200,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Vertex Pharmaceuticals Inc (Call) for a number of months, seems to be less bullish one the $39.50 billion market cap company. The stock increased 0.02% or $0.03 during the last trading session, reaching $155.02. About 1.52M shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 32.80% since June 17, 2017 and is uptrending. It has outperformed by 20.23% the S&P500. Some Historical VRTX News: 01/05/2018 – L3 TO SELL VERTEX AEROSPACE TO AMERICAN INDUSTRIAL PARTNERS; 20/04/2018 – L3 Vertex bidders submit refresh bids; 09/03/2018 – L3 management meets with bidders for Vertex divest; 29/03/2018 – Vertex Pharmaceuticals: White Will Begin Her Role With Vertex on May 21; 13/04/2018 – CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018; 29/03/2018 – Vertex Appoints Kimberly White as Chief Commun Officer; 27/04/2018 – Top 3 today — #1 Vertex’s rapid-fire PhIII program hits a roadblock at the FDA. Will regulators force rival Galapagos to slow down too? $VRTX $GLPG; 23/04/2018 – STAT Plus: U.K. ministers urge Vertex to reach pricing deal on its cystic fibrosis drug; 04/04/2018 – Q-STATE BIOSCIENCES & VERTEX PHARMACEUTICALS ENTER PACT; 26/04/2018 – STAT Plus: Vertex’s latest cystic fibrosis drug reports strong sales in first quarter since approval

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on July, 25. They expect $0.42 earnings per share, up 320.00% or $0.32 from last year’s $0.1 per share. VRTX’s profit will be $107.03 million for 92.27 P/E if the $0.42 EPS becomes a reality. After $0.54 actual earnings per share reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -22.22% negative EPS growth.

Artal Group Sa, which manages about $7.99 billion US Long portfolio, upped its stake in Incyte Corp (NASDAQ:INCY) by 50,000 shares to 300,000 shares, valued at $25.00 million in 2018Q1, according to the filing. It also increased its holding in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) by 300,000 shares in the quarter, for a total of 500,000 shares, and has risen its stake in Xencor Inc (NASDAQ:XNCR).

Investors sentiment decreased to 1.15 in Q1 2018. Its down 0.19, from 1.34 in 2017Q4. It dived, as 39 investors sold VRTX shares while 189 reduced holdings. 76 funds opened positions while 186 raised stakes. 232.72 million shares or 0.10% more from 232.48 million shares in 2017Q4 were reported. Wetherby Asset Mngmt Inc holds 0.09% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 4,078 shares. Fund Management Sa invested in 51,228 shares. Berkshire Asset Limited Liability Co Pa holds 1,863 shares. Citigroup Incorporated invested in 185,627 shares or 0.02% of the stock. Wealthcare Cap Mngmt Ltd Limited Liability Company reported 33 shares. Bowen Hanes & Communication has invested 1.25% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). First Tru Lp holds 476,971 shares or 0.18% of its portfolio. Oakmont Prtn reported 2,000 shares. Tekla Capital Ltd Company owns 614,084 shares or 3.89% of their US portfolio. Cap Ww Investors has 9.00 million shares for 0.33% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) reported 131,910 shares. Mason Street Advsr Ltd Llc holds 0.14% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 35,367 shares. Caisse De Depot Et Placement Du Quebec holds 5,305 shares. Captrust Advisors reported 53 shares. Gam Holding Ag has 6,600 shares.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Nasdaq.com which released: “Buy These 2 Biotech Stocks on the Dip After an FDA Delay” on June 05, 2018, also Fool.com with their article: “Now’s the Time to Buy These 3 Stocks” published on June 08, 2018, Nasdaq.com published: “Is Crispr Therapeutics Stock a Bad News Buy?” on May 31, 2018. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Globenewswire.com and their article: “CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 …” published on May 30, 2018 as well as Investorplace.com‘s news article titled: “After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall” with publication date: June 05, 2018.

Since January 2, 2018, it had 0 buys, and 50 sales for $88.91 million activity. The insider Sachdev Amit sold $7.33 million. 23,905 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $3.61 million were sold by LEIDEN JEFFREY M. On Friday, January 5 the insider Bhatia Sangeeta N. sold $1.68M. $33,804 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by SMITH IAN F. On Wednesday, April 25 the insider Parini Michael sold $6.49 million. 8,969 shares were sold by Arbuckle Stuart A, worth $1.52M.

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals had 102 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by Guggenheim on Wednesday, January 31 with “Buy”. The rating was initiated by Oppenheimer with “Perform” on Thursday, December 15. The firm has “Outperform” rating by Credit Suisse given on Tuesday, February 13. H.C. Wainwright downgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Monday, October 24. H.C. Wainwright has “Neutral” rating and $85 target. BMO Capital Markets maintained it with “Buy” rating and $182.0 target in Monday, September 25 report. The stock has “Buy” rating by Oppenheimer on Tuesday, July 18. BTIG Research initiated the shares of VRTX in report on Friday, September 29 with “Buy” rating. Argus Research maintained the stock with “Buy” rating in Thursday, February 4 report. As per Friday, September 29, the company rating was maintained by Stifel Nicolaus. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Jefferies on Sunday, August 20.

Among 40 analysts covering Mastercard Incorporated (NYSE:MA), 35 have Buy rating, 0 Sell and 5 Hold. Therefore 88% are positive. Mastercard Incorporated had 131 analyst reports since July 21, 2015 according to SRatingsIntel. Wells Fargo maintained the shares of MA in report on Tuesday, January 9 with “Buy” rating. The rating was maintained by RBC Capital Markets on Friday, October 30 with “Outperform”. The firm has “Overweight” rating by Piper Jaffray given on Thursday, December 31. The company was maintained on Thursday, February 1 by Susquehanna. The rating was maintained by Piper Jaffray on Tuesday, October 31 with “Buy”. The stock has “Overweight” rating by Barclays Capital on Thursday, September 8. The rating was maintained by RBC Capital Markets with “Top Pick” on Friday, June 16. The stock of Mastercard Incorporated (NYSE:MA) earned “Outperform” rating by Cowen & Co on Wednesday, September 30. The stock of Mastercard Incorporated (NYSE:MA) has “Hold” rating given on Thursday, February 1 by Sandler O’Neill. KeyBanc Capital Markets maintained it with “Buy” rating and $165.0 target in Wednesday, October 18 report.

Analysts await Mastercard Incorporated (NYSE:MA) to report earnings on July, 26. They expect $1.54 earnings per share, up 40.00% or $0.44 from last year’s $1.1 per share. MA’s profit will be $1.61 billion for 32.39 P/E if the $1.54 EPS becomes a reality. After $1.50 actual earnings per share reported by Mastercard Incorporated for the previous quarter, Wall Street now forecasts 2.67% EPS growth.

Autus Asset Management Llc, which manages about $447.84 million and $552.96 million US Long portfolio, upped its stake in Ishares Tr (PFF) by 11,293 shares to 283,396 shares, valued at $10.64M in 2018Q1, according to the filing. It also increased its holding in Vanguard Index Fds (VNQ) by 8,590 shares in the quarter, for a total of 115,903 shares, and has risen its stake in Vanguard Index Fds (VO).

Since January 2, 2018, it had 0 buys, and 8 insider sales for $59.23 million activity. Another trade for 17,496 shares valued at $3.25M was made by Vosburg Craig on Thursday, May 3. 30,628 shares were sold by Murphy Timothy H, worth $5.53 million on Monday, March 19. 3,993 shares were sold by Fraccaro Michael, worth $692,252 on Monday, April 9. 239,020 Mastercard Incorporated (NYSE:MA) shares with value of $44.45 million were sold by BANGA AJAY. CARLUCCI DAVID R sold 5,950 shares worth $1.09M. 5,000 shares were sold by Haythornthwaite Richard, worth $866,104.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Ash

Leave a Reply

Your email address will not be published. Required fields are marked *